Not sure what your point here is, but the first people to undergo risky experimental treatments like that are people already close to death. The fact that they died doesn’t necessarily mean the experiment was bad.
Slayman, who had end-stage kidney disease, underwent the transplant in March at Massachusetts General Hospital in Boston at age 62.
The hospital said in a statement on Saturday that there was “no indication” that his death was the result of the transplant. The transplant surgeon had said he hoped the transplant would function for at least two years.
And the second story is completely different. Heart transplants and gene therapy are completely different things.
As part of a trial run by Cambridge University, Opal received an infusion of a working copy of the OTOF gene in her right ear. The surgical procedure took only 16 minutes and was carried out just before she reached her first birthday.
Opal has tolerated the procedure and the gene therapy itself well, and she’s experienced no adverse effects following the treatments
Add comment